Overview

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD

Phase:

Phase 2

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Formoterol Fumarate
Tiotropium Bromide